Specification
This product does not include any hardware. Please refer to the following minimum software and hardware requirements (or above):
Operating System: iPadOS 16, iOS 14, API Level 21
Processor: A12Z Bionic Chip, A14, Snapdragon 888
Memory: 6GB RAM
Storage: 64GB internal storage
Benefits
Specifically Designed for Cardiac Ultrasound
Optimized interface and features tailored to the characteristics of cardiac imaging, enhancing annotation efficiency and diagnostic accuracy.
· Support for Multiple Image Formats
Compatible with various medical image formats such as DICOM, JPEG, and PNG, ensuring high interoperability with existing imaging systems.
· Visualized Image Display Platform
Offers a clear and interactive interface for image visualization, assisting clinicians in accurate interpretation and manipulation.
· Annotation and Processing Tools
Built-in basic image processing tools (e.g., zoom, resize, contrast adjustment) with annotation support to improve labeling efficiency.
· Automated Export of Annotated Reports
Annotation results can be exported in report formats, facilitating storage, review, and integration with other systems.
· Improved Diagnostic Workflow Efficiency
Reduces manual operations and documentation time for physicians, accelerating diagnosis and report generation.
Business Partners
GE HEALTHCARE、Aco Healthcare Co., Ltd、TRUST BIO-SONICS INC.
Success Stories
Top 10 in 2025 Computex InnoVEX Selection
Medical Device Manufacturing License – QMS2351 and QMS5518, Ministry of Health and Welfare
"Daikso" Medical Image Label System (Non-Sterile) (Taiwan FDA – MOHW-MD-No.010221)
”Daikso” Cardiac Ultrasound Imaging Marking Aided System (Non-Sterile) (Taiwan FDA – MOHW-MD-No. 010267)
”Daikso” Hip Joint Ultrasound Imaging Marking Aided System(Non-Sterile) (Taiwan FDA – MOHW-MD-No. 010275)
”Daikso” Thyroid Ultrasound Imaging Marking Aided System(Non-Sterile) (Taiwan FDA – MOHW-MD-No. 010293)
Approved in 2023 by the Ministry of Digital Affairs: AI Program II (Total Funding: NTD 12M)
Medical Device Manufacturer License (MD6101007063)
Daikso’s core technologies originate from extensive hands-on experience in medical imaging AI, and have been recognized by multiple world-class competitions, including:
Ranked No. 1 2022 MICCAI DFUC
Finalists in Top Five Finalist - EndoCV 2022
Ranked No. 1- "Paper with Code" in 2021
8th place(1200+ teams) in validation phase - BraTS 2021, MICCAI
Ranked No. 1 Paper with Code AI Ranking, 2021
Ranked No. 1 Adaptive Computing Challenge 2021, AMD-Xilinx
The only 1 polyp detection AI library serving in AMD-Xilinx AI Library
Ranked No. 2- MedAI 2021 in instrument segmentation
Ranked No. 3 - MedAI 2021 in polyp segmentation
National/International Medical Device Legal Permit No.
Taiwan FDA – MOHW-MD-No.010267